Retatrutide
GIP + GLP-1
A fast-rising triple-agonist candidate with eye-catching early data and high editorial curiosity.
How It Works
Retatrutide activates three metabolic pathways at once, combining appetite suppression with broader energy-expenditure effects.
Practical Information
injection
Retatrutide is covered as an injectable next-generation obesity compound, with practical questions centered on trial-stage expectations rather than routine sourcing.
Published obesity-trial coverage frames retatrutide as once-weekly subcutaneous dosing with dose escalation under study conditions.
Related Articles
See all 1 article →Retatrutide vs Tirzepatide: Bigger Promise, or Better Right Now?
Tirzepatide is the settled, approved option you can start using today. Retatrutide shows bigger weight-loss potential but remains investigational. Your pick depends on whether you want certainty now or the highest ceiling later.
4 min read